NVO logo

NVO
Novo Nordisk A/S

30,061
Mkt Cap
$165.49B
Volume
12.25M
52W High
$93.80
52W Low
$43.08
PE Ratio
14.14
NVO Fundamentals
Price
$48.74
Prev Close
$49.12
Open
$48.73
50D MA
$53.26
Beta
0.85
Avg. Volume
22.4M
EPS (Annual)
$3.49
P/B
7.15
Rev/Employee
$679,358.45
$242,651.58
Loading...
Loading...
News
all
press releases
Stocks Steady After Strong Jobs Data Dims Rate-Cut Bets The Close 2/11/2026
Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Yardeni Research's Ed...
Bloomberg Markets and Finance-YouTube·7h ago
News Placeholder
More News
News Placeholder
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly
Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.
Stocktwits·9h ago
News Placeholder
Novo says it's suing Hims to stop obesity drug copycats
Novo Nordisk Chief Executive Officer Maziar Mike Doustdar says it's suing Hims & Hers for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the...
Bloomberg Markets and Finance-YouTube·10h ago
News Placeholder
Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing
Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg's Katie Greifeld to discuss GLP-1 supply, pricing and the company's lawsuit...
Bloomberg Markets and Finance-YouTube·10h ago
News Placeholder
Novo Nordisk faces a defining year in the obesity drug market. It's off to a dramatic start
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share...
CNBC: Business·11h ago
News Placeholder
Novo CEO blasts 'mass compounding' of GLP-1 drugs as safety battle escalates
GLP-1 weight-loss drugs are now the focus of a heated legal battle, with a leading drugmaker warning that copycat versions pose a risk to patient safety.'When you go and try to source raw materials...
FOXBusiness.com - Business/Financial·14h ago
News Placeholder
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S...
CNBC: US News·15h ago
News Placeholder
Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?
NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.
Zacks·16h ago
News Placeholder
Wesbanco Bank Inc. Sells 97,165 Shares of Novo Nordisk A/S $NVO
Wesbanco Bank Inc. trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 55.9% in the third quarter, according to the company in its most recent filing with the Securities...
MarketBeat·17h ago
News Placeholder
Novo Nordisk A/S (NYSE:NVO) Lowered to Strong Sell Rating by Zacks Research
Zacks Research downgraded Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Monday...
MarketBeat·18h ago
<
1
2
...
>

Latest NVO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.